ReviewTranslational cancer research2026
Exosomal miRNA as a biomarker for diagnosis and prognosis, and a new target for regulating treatment resistance in DLBCL: a research progress narrative review.
Review in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Exosomes, as key mediators of intercellular communication, carry microRNAs (miRNAs) that play central roles in anticancer drug resistance by regulating the immune status of the tumor microenvironment (TME) and drug-metabolic pathways. In recent years, advances in single vesicle analysis have greatly promoted mechanistic studies on exosomal miRNAs in diffuse large B-cell lymphoma (DLBCL). This article aims to comprehensively review recent advances in the study of exosomal miRNAs in DLBCL. This review explores the value of exosomal miRNAs as tumor biomarkers in diagnosis and prognostic evaluation of DLBCL, and provides an in-depth analysis of molecular networks underlying DLBCL drug resistance mediated through exosomal miRNAs. Methods: This study conducted a literature review by searching the PubMed and Web of Science databases to identify the latest research findings regarding the roles of exosomal miRNAs as tumor biomarkers in diagnosis and prognostic evaluation of DLBCL, and the mechanisms by which exosomal miRNAs regulates DLBCL drug resistance. Based on these findings, a narrative review was generated. Key Content and Findings: This article introduces the biogenesis of exosomal miRNA and research progress on exosomal miRNAs as biomarkers in the diagnosis and prognosis of DLBCL. It summarizes the research progress on the mechanisms of exosomal miRNA in regulating therapeutic resistance in DLBCL. And it also discusses the current translational studies using exosomal miRNAs to control drug resistance in DLBCL, and challenges of using extracellular vesicle (EV)-derived miRNAs. These advances will help provide more new strategy for reversing DLBCL drug resistance in the future. Conclusions: Exosomal miRNAs can serve as biomarkers for the diagnosis and prognostic assessment of DLBCL and are associated with DLBCL treatment resistance. Currently, there has been significant progress in research on the mechanisms by which exosomal miRNAs regulate DLBCL resistance, with some mechanisms already validated. It is expected that through more in-depth in vivo and in vitro studies in the future, mature therapeutic targets can be developed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.